Clinical Trial SuccessNeflamapimod-treated patients showed a 54% risk reduction in clinically significant worsening vs. control at the 32-week timepoint, which improved to 64% among patients with minimal evidence of Alzheimer's disease co-pathology.
Investment PotentialThe analyst's recommendation is a 'Buy' with a price target of $20.00, reflecting confidence in the company's future performance.
Regulatory ProgressFDA may see the totality of the dataset and green light proceeding to Phase 3.